CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...
Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback